Shares of ConvaTec Group PLC (LON:CTEC) have received an average recommendation of “Hold” from the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is GBX 206.10 ($2.69).
A number of equities research analysts have recently issued reports on CTEC shares. Peel Hunt dropped their price objective on ConvaTec Group from GBX 220 ($2.87) to GBX 170 ($2.22) and set a “hold” rating on the stock in a research note on Thursday, October 25th. Jefferies Financial Group dropped their price objective on ConvaTec Group from GBX 280 ($3.66) to GBX 210 ($2.74) and set a “buy” rating on the stock in a research note on Wednesday, October 31st. Deutsche Bank reiterated a “sell” rating on shares of ConvaTec Group in a research note on Friday, October 5th. Royal Bank of Canada reiterated an “outperform” rating and set a GBX 240 ($3.14) price objective on shares of ConvaTec Group in a research note on Wednesday, August 8th. Finally, JPMorgan Chase & Co. cut ConvaTec Group to a “neutral” rating and dropped their price objective for the stock from GBX 280 ($3.66) to GBX 183 ($2.39) in a research note on Tuesday, October 16th.
In other ConvaTec Group news, insider Frank Schulkes purchased 65,000 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were acquired at an average price of GBX 150 ($1.96) per share, for a total transaction of £97,500 ($127,401.02).
About ConvaTec Group
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as for traumatic injury, burns, invasive surgery, and other causes.
See Also: Book Value Per Share in Stock Trading
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.